Opinions of gastroenterologists about intestinal microbiota modulating agents: results of the survey in focus groups

Cover Page

Cite item

Full Text

Abstract

Aim. To study the opinions of gastroenterologists about drugs affecting the intestinal microflora.

Materials and methods. A qualitative survey was conducted in focus groups to study the patterns of prescribing drugs that regulate intestinal microflora in chronic gastrointestinal diseases. The survey included only outpatient gastroenterologists who managed patients with irritable bowel syndrome, an uncomplicated diverticular disease with clinical manifestations and excessive bacterial growth in the small intestine for at least 3 years.

Results. Physicians perceive the non-absorbable antibiotic rifaximin alpha as the drug of choice for treating these diseases; they are aware of its low bioavailability and suitability for repeated use. However, with severe clinical symptoms, some doctors tend to use systemic antibiotics before infectious or inflammatory complications are confirmed. It is due to the erroneous perception of systemic antibiotics as obviously more effective drugs than non-absorbable antibiotics. When choosing a drug, it is essential to consider the risk of antibiotic-associated diarrhea, adverse changes in the microflora, and the patient's comorbidities.

Conclusion. Surveyed gastroenterologists consider rifaximin alfa (Alfa Normix) the most suitable drug that helps in routine practice achieve the desired result with a minimum risk of adverse events. Many study participants are skeptical about the effect of probiotics due to the lack of evidence but emphasize their safety and the request for probiotics from patients. Not all doctors are aware of metabiotics. Prebiotics and dietary fibers are perceived as agents that affect both the intestinal microflora and the stool frequency. Some healthcare professionals are concerned about prebiotics and probiotics registered as dietary supplements, which can cause patient misunderstandings. Identified opinions about such agents can be used in training gastroenterologists and developing clinical guidelines.

About the authors

Oleg V. Golovenko

Russian Medical Academy of Continuous Professional Education

Email: drgolovenko@yandex.ru
ORCID iD: 0000-0002-7439-0983

D. Sci. (Med.)

Russian Federation, Moscow

Alexey O. Golovenko

Medical sanitary unit №14

Author for correspondence.
Email: golovenkoao@gmail.com
ORCID iD: 0000-0003-3244-4469

Gastroenterologist

Russian Federation, Moscow

References

  1. Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets. 2014;15(8):762-70. doi: 10.2174/1389450115666140606111402
  2. Bellini M, Tosetti C, Rettura F, et al. Translational Gap between Guidelines and Clinical Medicine: The Viewpoint of Italian General Practitioners in the Management of IBS. J Clin Med. 2022;11(13):3861. doi: 10.3390/jcm11133861
  3. Renjith V, Yesodharan R, Noronha JA, et al. Qualitative Methods in Health Care Research. Int J Prev Med. 2021;12:20. doi: 10.4103/ijpvm.IJPVM_321_19
  4. Anderson C. Presenting and evaluating qualitative research. Am J Pharm Educ. 2010;74(8):141. doi: 10.5688/aj7408141
  5. Rustom LBO, Sharara AI. The Natural History of Colonic Diverticulosis: Much Ado about Nothing? Inflamm Intest Dis. 2018;3(2):69-74. doi: 10.1159/000490054
  6. Ардатская М.Д., Ачкасов С.И., Веселов В.В., и др. Клинические рекомендации. Дивертикулярная болезнь. Колопроктология. 2021;20(3):10-27 [Ardatskaya MD, Achkasov SI, Veselov VV, et al. Clinical guidelines. Diverticular Disease. Koloproktologia. 2021;20(3):10-27 (in Russian)]. doi: 10.33878/2073-7556-2021-20-3-10-27
  7. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-78. doi: 10.14309/ajg.0000000000000501
  8. Krogsgaard LR, Engsbro AL, Bytzer P. Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort. Scand J Gastroenterol. 2018;53(9):1027-30. doi: 10.1080/00365521.2018.1500638
  9. Vinelli V, Biscotti P, Martini D, et al. Effects of Dietary Fibers on Short-Chain Fatty Acids and Gut Microbiota Composition in Healthy Adults: A Systematic Review. Nutrients. 2022;14(13):2559. doi: 10.3390/nu14132559
  10. Dixon-Woods M, Critchley S. Medical and lay views of irritable bowel syndrome. Fam Pract. 2000;17(2):108-13. doi: 10.1093/fampra/17.2.108
  11. Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38(10):1031-8. doi: 10.1080/00365520310004524
  12. Tursi A, Franceschi M, Elisei W, et al. The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study. Ann Gastroenterol. 2021;34(2):208-13. doi: 10.20524/aog.2020.0560
  13. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95 [Ivashkin VT, Maev IV, Shelygin YuA, et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95 (in Russian)]. doi: 10.22416/1382-4376-2021-31-5-74-95
  14. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi: 10.1136/gutjnl-2021-324598
  15. Li J, Zhu W, Liu W, et al. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore). 2016;95(4):e2534. doi: 10.1097/MD.0000000000002534
  16. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33(8):902-10. doi: 10.1111/j.1365-2036.2011.04606.x
  17. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9):667-70. doi: 10.1038/ja.2014.106
  18. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14(2):51-6.
  19. Wang Y, Chen N, Niu F, et al. Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs. Int J Colorectal Dis. 2022;37(11):2263-76. doi: 10.1007/s00384-022-04261-0
  20. van der Geest AM, Schukking I, Brummer RJM, et al. Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Benef Microbes. 2022;13(3):183-94. doi: 10.3920/BM2021.0123
  21. Asha MZ, Khalil SFH. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ Med J. 2020;20(1):e13-24. doi: 10.18295/squmj.2020.20.01.003
  22. El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med. 2017;40(3):607-13. doi: 10.3892/ijmm.2017.3072
  23. Furnari M, Parodi A, Gemignani L, et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010;32(8):1000-6. doi: 10.1111/j.1365-2036.2010.04436.x
  24. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-9. doi: 10.1111/j.1572-0241.2003.07234.x
  25. Yang J, Lee HR, Low K, et al. Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-74. doi: 10.1007/s10620-007-9839-8
  26. Ponziani FR, Zocco MA, D'Aversa F, et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491-9. doi: 10.3748/wjg.v23.i25.4491
  27. Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309-25. doi: 10.2147/CEG.S89999
  28. Ponziani FR, Scaldaferri F, Petito V, et al. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig Dis. 2016;34(3):269-78. doi: 10.1159/000443361
  29. Blandizzi C, Viscomi GC, Scarpignato C. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Devel Ther. 2014;9:1-11. doi: 10.2147/DDDT.S72572
  30. Blandizzi C, Viscomi GC, Marzo A, Scarpignato C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014;85:39-44. doi: 10.1016/j.phrs.2014.05.001

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (82KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).